Pd14-03 Bladder Cancer Organoids Serve as a Useful System to Mirror the Characteristics of Parental Tumours

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (PD14)1 May 2024PD14-03 BLADDER CANCER ORGANOIDS SERVE AS A USEFUL SYSTEM TO MIRROR THE CHARACTERISTICS OF PARENTAL TUMOURS Hongda Zhao, Kang Liu, Xuan Chen, Hongwei Wu, Peter Ka-Fung Chiu Chiu, Chi-Fai Ng, and Jeremy Yuen-Chun Teoh Hongda ZhaoHongda Zhao , Kang LiuKang Liu , Xuan ChenXuan Chen , Hongwei WuHongwei Wu , Peter Ka-Fung Chiu ChiuPeter Ka-Fung Chiu Chiu , Chi-Fai NgChi-Fai Ng , and Jeremy Yuen-Chun TeohJeremy Yuen-Chun Teoh View All Author Informationhttps://doi.org/10.1097/01.JU.0001009472.76470.8c.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Bladder cancer is characterized by its heterogeneity, leading to highly variable treatment responses to different drugs. Therefore, the establishment of a precise and patient-specific pre-clinical model is crucial to accurately assess the sensitivity of individual patients to various treatment methods. METHODS: To establish an in vitro model for precise and patient-specific treatment, fresh tumour tissues were collected from bladder cancer patients. Immunohistochemistry (IHC) staining and whole-exome sequencing (WES) were performed to confirm the consistency between the organoids and parental tissues. Additionally, organoid-derived xenografts (ODXs) were developed to demonstrate the efficient interconversion between organoids and ODXs. RESULTS: Currently, we have collected 45 tumour tissues, with approximately 60% of cases forming in vitro organoids. Eight long-term patient-derived organoid lines were established, including one from a a BCG treatment failure patient. These organoid lines showed the ability of serial passaging, cryopreservation, and recovery. Besides, Four lines successfully formed ectopic xenografts in vivo. The results of immunohistochemistry (IHC) staining and whole-exome sequencing (WES) confirmed that the organoids faithfully recapitulated the histological features and mutational spectrum of the parental tumours. Additionally, our organoids were used to assess the response to standard-of-care (SOC) and FDA-approved drugs. The representative results showed that PDOs have heterogeneous responses to SOC drugs, and they could successfully mimic the drug response patterns from parental tumours. CONCLUSIONS: In summary, this study has successfully created a valuable biobank resource consisting of bladder cancer organoids, covering a wide range of disease stages. Importantly, it has been demonstrated that patient-derived organoids (PDOs) retain the heterogeneity and the mutational burden observed in the original tumours. Furthermore, the PDOs have shown potential for contributing to personalized treatment. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e354 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Hongda Zhao More articles by this author Kang Liu More articles by this author Xuan Chen More articles by this author Hongwei Wu More articles by this author Peter Ka-Fung Chiu Chiu More articles by this author Chi-Fai Ng More articles by this author Jeremy Yuen-Chun Teoh More articles by this author Expand All Advertisement PDF downloadLoading ...